Close Menu

NEW YORK (360Dx) – San Diego-based TearLab announced yesterday that its next-generation, multiplex diagnostics platform for human tear samples has received CE marking as an in vitro diagnostic medical device.

The CE mark also covers an assay for response to dry eye disease therapy, which measures both osmolarity, a measure of solute concentration, and an inflammation biomarker.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.